CurrentOscar HealthPolicy N/A

General Inflammation Testing (CRP and ESR) Coverage Criteria

Customize your policy alerts

Sign up for all Oscar Health policy alerts

Know when Oscar Health releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs coverage and reimbursement for C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) testing for inflammatory conditions for Oscar Health members. It describes covered indications, test preferences, and limitations applicable to providers submitting claims.

Policy Summary

PayerOscar Health

PolicyGeneral Inflammation Testing (CRP and ESR) Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateOct 1, 2026

Last ReviewJun 16, 2026

Next Review DateJun 16, 2026

Key ActionOrder CRP as the preferred single inflammatory marker when either CRP or ESR is allowed; if both are ordered where either is allowed, only CRP will be approved.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

CRPPreferred biomarker when CRP or ESR are allowed

No ESR screeningESR not for screening

Only CRPIf both ordered only CRP approved

ManyConditions referenced

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentOscar HealthPolicy N/A

General Inflammation Testing (CRP and ESR) Coverage Criteria

Customize your policy alerts

Sign up for all Oscar Health policy alerts

Know when Oscar Health releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerOscar Health

PolicyGeneral Inflammation Testing (CRP and ESR) Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateOct 1, 2026

Last ReviewJun 16, 2026

Next Review DateJun 16, 2026

Key ActionOrder CRP as the preferred single inflammatory marker when either CRP or ESR is allowed; if both are ordered where either is allowed, only CRP will be approved.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

CRPPreferred biomarker when CRP or ESR are allowed

No ESR screeningESR not for screening

Only CRPIf both ordered only CRP approved

ManyConditions referenced

06/16/2026Publication date

Coverage Criteria for CRP and ESR

inv-01: Covered when diagnosed or suspected inflammatory condition

Measurement of CRP and/or ESR meets criteria for the following diagnosed or suspected inflammatory conditions as specified below. When both are allowed, CRP is preferred and simultaneous ordering may result in approval of only CRP.

General inclusion: Measurement of CRP and/or ESR MEETS CRITERIA for the conditions specified in Note 1.

See condition-specific preferences and frequencies in policy Notes

Exclusions for screening/general exam: For individuals without a diagnosed inflammatory condition, measurement of ESR DOES NOT MEET CRITERIA. Measurement of CRP and/or ESR during general exam without abnormal findings DOES NOT MEET CRITERIA.

Condition-specific preferences (examples): Policy lists many conditions with test preference and frequency rules. Examples include: Acute Hematogenous Osteomyelitis (CRP preferred; tests to confirm diagnosis and every 2–3 days early, then weekly until normalization), Periprosthetic Joint Infections (CRP and ESR), Rheumatoid Arthritis (CRP or ESR; prior to treatment; every 1–3 months during active disease; annually when inactive), Polymyalgia Rheumatica (CRP or ESR; at initial diagnosis; every 3 months during long-term steroid therapy), Large Vessel Vasculitis (CRP and ESR; to confirm diagnosis; every 1–3 months first year; every 3–6 months thereafter)

See full table in policy Notes for other conditions such as Castleman's disease, Hodgkin lymphoma, IBS, SLE, T-cell lymphomas, etc.

inv-02: Test selection for undifferentiated inflammation

Covered when choosing the most clinically informative single marker:

Single-marker selection: CRP is generally preferred as the first-line test for acute-phase inflammation because it has marginally superior diagnostic accuracy for infections and returns to normal more quickly; ESR may be selected when CRP is unavailable or for specific conditions where ESR has demonstrated value (e.g., Hodgkin lymphoma staging, SLE evaluation where ESR can be elevated despite low CRP).

Based on comparative diagnostic studies and professional recommendations.

inv-03: Use of CRP/ESR in prosthetic joint infection (PJI)

Covered as supportive diagnostic biomarkers when used alongside clinical assessment and definitive diagnostics:

PJI supportive use: CRP and ESR may be used as minor diagnostic criteria for PJI; CRP has higher diagnostic odds ratio than ESR in meta-analysis, but both can have false negatives particularly with low-virulence organisms; lower cutoffs have been proposed to improve sensitivity (e.g., ESR 10 mm/h, CRP 5 mg/L in one study).

Should not replace microbiologic culture or established diagnostic definitions but may inform preoperative evaluation.

inv-04: Hodgkin lymphoma staging and follow-up

Covered when applied per NCCN guideline recommendations:

Hodgkin lymphoma indication: ESR measurement within six months of diagnosis is essential for staging and risk classification in Classic Hodgkin Lymphoma and is used in follow-up if elevated at diagnosis; ESR thresholds (for example <50 versus ≥50 mm/h) influence treatment algorithm selection and radiation dosing. CRP is not specified by NCCN for CHL in these references.ESR <50 vs ≥50 mm/h

Follow NCCN timing and record ESR when elevated at diagnosis for recommended follow-up.

inv-05: Neonatal early-onset sepsis

Covered for targeted diagnostic use rather than routine screening:

Early-onset sepsis utility: CRP may be used to support evaluation for neonatal early-onset sepsis but has variable sensitivity depending on timing after birth; routine serial CRP testing was not shown to improve patient outcomes and therefore routine CRP screening is of limited utility. Use CRP in context with timing relative to blood cultures and other clinical factors.CRP ≥10 mg/L used in study for culture-confirmed EOS

Sensitivity increases when CRP obtained 24–72 hours after culture but specificity decreases.

inv-06: Inflammatory bowel disease (IBD) evaluation

Covered as an adjunctive test:

IBD evaluation: CRP can aid differentiation between IBD and IBS and serves as an adjunct to clinical and endoscopic findings, but a normal CRP does not exclude IBD; use in combination with other markers and assessments.

AGA recommends against routine screening with CRP/ESR for IBD; use fecal markers where appropriate.

inv-07: Guideline-based monitoring and diagnostic recommendations

Recommendations and monitoring intervals cited by specialty guidelines

Giant cell arteritis (GCA): Document symptoms and obtain baseline full blood count, CRP and ESR before or immediately after starting high-dose glucocorticoids; include clinical monitoring with ESR/CRP as inflammation markers. Frequency individualized—visits may be every 1–3 months in the first year and every 3–6 months thereafter per EULAR; ACR recommends clinical monitoring and advises against escalating immunosuppression for marker rise alone without other signs.

Follow society recommendations for monitoring and clinical correlation.

Polymyalgia rheumatica (PMR): Obtain baseline laboratory workup including RF/ACPA, CRP and/or ESR prior to therapy; monitor ESR or CRP every three months during long-term steroid therapy with more frequent visits early in course per BSR/EULAR guidance.

Frequency may vary from 1–4 weeks until remission to 1–4 months in first year per guidelines.

Rheumatoid arthritis (RA): Use validated composite measures (e.g., DAS28 which can use CRP or ESR) to assess disease activity; monitor as frequently as every 1–3 months during active disease and less frequently once target reached. NICE recommends monthly CRP and disease activity measurement in specialist care until remission or low disease activity.

inv-08: Guideline-based diagnostic and monitoring recommendations

Relevant clinical guidance and monitoring recommendations cited in policy

AAOS on PJI: ESR and CRP can aid in preoperative diagnosis of prosthetic joint infection but are not perfectly accurate and should not be used as sole diagnostic tests; neither marker identifies PJI microbiology.

Guideline endorsed by IDSA, ACR, SNMMI.

Pediatric AHO initial and monitoring: In suspected acute hematogenous osteomyelitis in children perform serum CRP on initial evaluation; CRP serves as baseline for serial monitoring and should be measured every 2–3 days early in therapy then weekly until normalization or clear trend is evident. Avoid serum procalcitonin for this purpose.every 2-3 days initially then weekly

Pediatric Infectious Diseases Society/IDSA 2021 guideline.

British Columbia guidance: CRP is the preferred first test for inflammatory or infectious conditions; there is no indication to order ESR when CRP is elevated. Outpatient ESR may be performed only with a written indication on the requisition; if both CRP and ESR are ordered together most outpatient labs will perform only CRP because only CRP is payable. hsCRP should be specifically requested when used for cardiovascular risk stratification.

Measurement of erythrocyte sedimentation rate (ESR) for individuals without a diagnosed inflammatory condition does not meet criteria. The policy explicitly excludes routine ESR testing in asymptomatic persons or during general examinations without abnormal findings; ESR measurement is covered only when performed for specified diagnosed or suspected inflammatory conditions. Providers should confirm that the member’s clinical presentation and benefit coverage support ESR testing before ordering.

Ordering multiple inflammatory markers (for example, CRP and ESR simultaneously) to attempt to increase diagnostic accuracy is discouraged. Evidence from a large prospective cohort showed that adding a second marker produced minimal improvement in overall diagnostic performance, and the policy states that when either CRP or ESR is allowed, CRP is preferred and if both are ordered only CRP will be approved.

The American Gastroenterological Association (AGA) advises against using ESR or CRP to screen for inflammatory bowel disease (IBD) in most patients (conditional recommendation, low-quality evidence). While CRP may be reasonable if fecal markers (eg, calprotectin) are unavailable or not covered, routine use of ESR or CRP as a screening test for IBD is generally not recommended.

British Columbia guidance prefers CRP as the first test for suspected inflammatory or infectious conditions and states there is no indication to order ESR when CRP is elevated. The BC outpatient payment schedule may require a written indication on the requisition for ESR, and many outpatient laboratories will only perform CRP when both tests are requested because only CRP is payable in that schedule.

Routine measurement of ESR in individuals without a diagnosed inflammatory condition is considered not medically necessary and does not meet coverage criteria. ESR should be ordered only for indications explicitly listed in the policy and supported by clinical documentation.

Routine serial CRP testing for evaluation of neonatal early‑onset sepsis (EOS) without other clinical indications demonstrated increased evaluations and antibiotic use without improved detection or mortality benefit in a large cohort. Therefore, routine serial CRP screening in neonates absent specific clinical indications is of limited utility and not supported.

ACR guidance on Hodgkin lymphoma follow‑up notes limited data supporting routine blood testing to detect relapse. ESR is included among routine blood tests in some follow‑up variants, but the majority of recurrences are identified by history and physical exam rather than routine laboratory screening, and routine serial ESR/CBC/chemistry has limited value for relapse detection.

For prosthetic joint infection (PJI) evaluation, neither CRP nor ESR should be used alone as the sole diagnostic test. The AAOS supports use of ESR and CRP as adjunctive preoperative tests but emphasizes that neither biomarker is perfectly accurate and both can be false negative; microbiologic culture and established diagnostic criteria remain essential.

Specific Covered Indications

inv-52: Diagnosis confirmation and monitoring of inflammatory conditions (RA, PMR, GCA, SLE, AS, PJI, AHO, Hodgkin lymphoma, Castleman disease, IBD exclusion, large vessel vasculitis, general inflammation) — test preference and frequency per condition

Diagnosis confirmation and monitoring of inflammatory conditions — test preference and frequency per condition:

Conditions covered: Measurement of CRP and/or ESR MEETS CRITERIA for diagnosis confirmation and monitoring of conditions including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), giant cell arteritis (GCA), systemic lupus erythematosus (SLE), ankylosing spondylitis, periprosthetic joint infection (PJI), acute hematogenous osteomyelitis (AHO), Hodgkin lymphoma, Castleman disease, irritable bowel syndrome/IBD exclusion, large vessel vasculitis, and general inflammation.

Test preference (CRP vs ESR) and recommended monitoring frequency provided per condition in policy Notes; CRP preferred when either allowed.

Test preference and frequency examples: Examples: AHO—CRP preferred; measure to confirm diagnosis and every 2–3 days during early therapy then weekly until normalization. PJI—CRP and ESR supported as adjuncts. RA—CRP or ESR prior to treatment; every 1–3 months during active disease; annually when inactive. PMR—CRP or ESR at diagnosis; every 3 months during long-term steroid therapy. Hodgkin lymphoma—record ESR within six months of diagnosis and follow recommended follow-up intervals.

Refer to policy Notes table for full condition list and frequencies.

Recommended Monitoring Frequency and Limits

Condition-specific frequency examples

Acute hematogenous osteomyelitis (AHO)CRP preferred — measure every 2–3 days during the early therapeutic course, then weekly until normalization (or a clear trend toward normalization).

Rheumatoid arthritis (RA)CRP or ESR — prior to treatment; every 1–3 months during active disease; annually when disease is inactive.

Polymyalgia rheumatica (PMR)CRP or ESR — at initial diagnosis; every 3 months during long-term steroid therapy.

Hodgkin lymphoma (HL)ESR indicated — follow-up every 3–6 months for 1–2 years, every 6–12 months for next 3 years, then annually thereafter as specified.

ESR/CRP — numeric frequency

Policy frequency mandateNo specific numeric testing frequency is mandated for ESR or CRP in the policy; monitoring intervals are provided by disease guidance.

Procedure Codes and Coding Notes

Test codes (not specified)mixed

not provided

Document does not list specific CPT/HCPCS/ICD codes for CRP or ESR tests in these chunks.

Applicable CPT Procedure CodesCPT

85651	Sedimentation rate, erythrocyte; non-automated
85652	Sedimentation rate, erythrocyte; automated
86140	C-reactive protein
86141	C-reactive protein; high sensitivity (hsCRP)

PJI ESR and CRP sensitivity thresholds

PJI high-sensitivity thresholds (study)One study identified ESR 10 mm/h and CRP 5 mg/L as cutoffs associated with ≥95% sensitivity for prosthetic joint infection.

Traditional MSIS cutoffsStandard MSIS thresholds are ESR 30 mm/h and CRP 10 mg/L, which the cited study found to have lower sensitivity and more false positives.

Combined threshold performanceCombined ESR 10 mm/h and CRP 5 mg/L in the study produced 100% sensitivity in the analyzed cohort.

Neonatal early-onset sepsis CRP cutoff

Neonatal EOS CRP cutoffIn the cited large NICU cohort, CRP ≥ 10 mg/L was used as the cutoff for culture‑confirmed early‑onset sepsis.

Timing effects

Provider Actions, Documentation, and Billing Guidance

Prior Authorization

Coverage only for specified diagnosed/suspected inflammatory conditions; prior auth depends on benefits

Measurement of CRP and/or ESR is covered only for the diagnosed or suspected inflammatory conditions specified in the policy notes; whether authorization is required depends on the member's benefit coverage and applicable state/federal rules.

Coverage limited to conditions listed in Note 1 (see policy Notes).
Prior authorization requirements are contingent on individual benefit coverage and state regulations.

Prior Authorization

No explicit prior authorization requirement stated

The policy text does not specify any explicit prior authorization requirements for CRP or ESR testing in the provided sections.

No payer prior‑auth rules for CRP/ESR are detailed in these document sections.

Ordering and Requisition Requirements

Billing Rule

Ordering and reimbursement contingent on member benefits and documentation

Ordering and reimbursement are contingent on member benefit coverage and appropriate documentation; this applies to both participating and non‑participating providers unless otherwise noted.

Verify member benefits and state/federal rules prior to ordering for authorization and reimbursement.
Policy guidance applies to participating and non‑participating providers unless stated otherwise.

Note

Follow guideline-recommended initial workup and monitoring intervals (e.g., PMR, early arthritis)

Guidelines cited in the policy recommend performing ESR and/or CRP as part of initial workup and ongoing monitoring for conditions such as polymyalgia rheumatica and early arthritis; clinicians should follow specialty guidance for timing and frequency.

Not Covered and Limitations

ESR testing for individuals without a diagnosed inflammatory condition and measurement of CRP/ESR during a general examination without abnormal findings are not covered. Coverage is limited to specified diagnosed or suspected inflammatory conditions, and when either marker is allowed CRP is the preferred test.

Routine simultaneous measurement of multiple inflammatory markers (eg, CRP plus ESR) for the sole purpose of improving diagnostic accuracy is not covered or discouraged. Large cohort data show minimal incremental diagnostic value from testing both markers, and the policy will generally approve only CRP if both are ordered where either is allowed.

Use of ESR or CRP to screen for IBD is generally not recommended by the AGA (conditional recommendation). Accordingly, use of these tests for routine IBD screening in asymptomatic patients is not covered, except in select circumstances when fecal testing is unavailable or not covered and CRP is judged clinically appropriate.

Per British Columbia guidance, there is no indication to order ESR when CRP is elevated. In some outpatient payment schedules ESR will be performed only if a written indication is provided; many outpatient laboratories will only perform CRP when both tests are ordered because only CRP is payable. These circumstances are treated as not covered unless the ESR has a documented, justified indication.

The policy text does not list explicit additional test or indication exclusions beyond those described above. Where exclusions are not explicitly stated, coverage decisions should follow the policy’s stated criteria and referenced guideline recommendations.

Background and Rationale

C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are non‑specific acute phase reactants used to detect and monitor systemic inflammation from tissue injury, autoimmune disease, and infection. CRP is synthesized by the liver and can rise rapidly in acute inflammation; ESR measures the rate at which erythrocytes settle in a tube over one hour and is influenced by sample method and noninflammatory factors. CRP is generally preferred when either test is allowed because of greater reproducibility and assay characteristics.

Definitions and Test Types

CRP definition

CRP — acute phase proteinC-reactive protein (CRP) is an acute phase protein synthesized by the liver that increases markedly during acute inflammation and is useful for monitoring inflammatory responses.

CRP assay variantsMultiple CRP assay formats exist including conventional CRP and high-sensitivity CRP (hsCRP) used for specific indications; FDA has issued assessment guidance for CRP assays.

Clinical interpretationCRP concentrations vary between individuals and laboratories; interpret results in clinical context.

ESR definition

ESR — Westergren and alternate methodsErythrocyte sedimentation rate (ESR) is measured by the Westergren method (distance red cells fall over one hour); alternate automated methods exist and may yield different results requiring interpretative comments.

Method variability

Policy Revision History

2026-06-16governance_approval

Governance approved the policy as original documentation.

2026-10-01effective_dateLatest

Policy became effective for use on 2026-10-01.

Policy Summary

PayerOscar Health

PolicyGeneral Inflammation Testing (CRP and ESR) Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateOct 1, 2026

Last ReviewJun 16, 2026

Next Review DateJun 16, 2026

Key ActionOrder CRP as the preferred single inflammatory marker when either CRP or ESR is allowed; if both are ordered where either is allowed, only CRP will be approved.

SourceLink

On This Page

ACR and NICE guidance cited.

Systemic lupus erythematosus (SLE): CRP is often low or normal unless infection; ESR may be raised in active SLE but is less reliable. BSR recommends CRP testing at diagnosis and every 1–3 months during active disease, then every 6–12 months once stabilized.

Interpret markers in clinical context due to SLE-specific limitations.

Prosthetic joint infection (PJI): ESR and CRP are supported to aid preoperative diagnosis of PJI but neither is definitive and should not be used as sole diagnostic tests.

AAOS endorses use but highlights limitations.

Acute hematogenous osteomyelitis (AHO) in children: Obtain serum CRP on initial evaluation to serve as baseline for sequential monitoring; monitor CRP every 2–3 days during early therapy, then weekly or periodically until normalization or clear trend toward normalization.every 2-3 days initially then weekly

Pediatric Infectious Diseases Society/IDSA 2021 guideline.

Inflammatory bowel disease (IBD) screening: AGA suggests against routine use of ESR or CRP to screen for IBD; CRP may be reasonable when fecal markers are unavailable or not covered.

Use alternative tests when appropriate.

Government of British Columbia guideline.

inv-53: Supportive evaluation of suspected infection, PJI, inflammatory disease activity monitoring, Hodgkin lymphoma staging and follow-up, Castleman disease minor diagnostic criteria

Supportive uses where inflammation markers aid clinical evaluation:

Suspected infection evaluation: CRP is preferred for acute infections due to higher sensitivity; ESR may be used where CRP is unavailable or per specific guideline recommendations.

CRP has marginally superior diagnostic accuracy for infections.

PJI and inflammatory disease monitoring: CRP and ESR may support evaluation of suspected prosthetic joint infection and monitoring of inflammatory disease activity (e.g., RA, PMR) but should be interpreted with clinical findings and other diagnostics.

Neither CRP nor ESR is definitive for PJI; use alongside microbiologic testing.

Hodgkin lymphoma and Castleman disease: ESR is essential for staging/classification of Classic Hodgkin Lymphoma and should be recorded within six months of diagnosis; for Castleman disease, elevated CRP (>10 mg/L) or ESR (>15 mm/h) are minor diagnostic criteria and CRP tracking is recommended (ESR acceptable if CRP unavailable).CRP >10 mg/L or ESR >15 mm/h

Follow NCCN recommendations for these hematologic conditions.

inv-54: Diagnosis and monitoring of GCA, PMR, RA, and SLE — baseline and periodic ESR/CRP testing as recommended by societies

Diagnosis and monitoring of selected rheumatologic conditions — baseline and periodic ESR/CRP testing as recommended by societies:

GCA and PMR: Guidelines recommend obtaining baseline CRP and/or ESR before or immediately after starting therapy for suspected GCA and including inflammation markers in routine monitoring; for PMR obtain baseline CRP/ESR and monitor every three months during long-term steroid therapy, with more frequent follow-up early in disease per BSR/EULAR.

Do not escalate immunosuppression for marker rise alone without other signs (ACR).

RA: Use validated composite disease activity measures (e.g., DAS28 which accepts CRP or ESR); monitor disease activity every 1–3 months during active RA and less frequently once remission/low disease activity achieved; NICE recommends monthly CRP and disease activity measurement in specialist care until remission.

ACR and NICE guidance cited.

SLE: BSR recommends CRP testing at diagnosis and every 1–3 months during active disease, then every 6–12 months once stabilized; interpret CRP cautiously as it may be low in active SLE unless infection is present.

ESR may be elevated in SLE but is less reliable due to hypergammaglobulinemia.

inv-55: Preoperative evaluation for suspected prosthetic joint infection (PJI) — ESR and CRP supported as aids

Preoperative evaluation for suspected prosthetic joint infection (PJI):

PJI preoperative aid: ESR and CRP are supported as aids in preoperative evaluation for suspected PJI but are not definitive diagnostic tests and should not replace microbiologic culture or established diagnostic workups.

AAOS endorses their use but emphasizes limitations and need for corroborating diagnostics.

inv-56: Initial evaluation and sequential monitoring of suspected pediatric acute hematogenous osteomyelitis (AHO) — serum CRP recommended

Initial evaluation and serial monitoring approach for suspected pediatric AHO:

Pediatric AHO baseline and monitoring: Obtain serum CRP on initial evaluation as baseline for sequential monitoring; CRP has limited diagnostic accuracy but is useful to follow trend. Recommended monitoring: every 2–3 days during early therapy, then weekly or periodically until normalization or clear trend toward normalization.every 2-3 days initially then weekly

Do not use serum procalcitonin for this purpose; ESR is no longer used routinely to diagnose pediatric AHO per guideline.

inv-57: Support diagnosis or monitoring of suspected inflammatory or infectious diseases — CRP preferred first-line; ESR adjunctive

Support for use of CRP as first-line inflammatory marker with ESR as adjunct in specific contexts:

First-line CRP preference: When evaluating suspected inflammatory or infectious disease, CRP is the preferred first-line test; ESR may be used as an adjunct when guideline-specified or when CRP is unavailable, but simultaneous ordering solely to improve diagnostic accuracy is discouraged and may not be approved.

Policy: if both CRP and ESR ordered where either is allowed, only CRP will be approved.

inv-58: General laboratory evaluation of inflammatory conditions as supported by cited clinical practice guidelines and regulatory reviews

General laboratory evaluation of inflammatory conditions as supported by cited clinical practice guidelines and regulatory reviews:

Guideline-referenced practice: Clinical guidance from professional societies and regulatory reviews supports use of CRP and ESR in specified conditions with condition-specific preferences and monitoring intervals; refer to cited guidelines for detailed recommendations.

See references (NCCN, AAOS, ACR, EULAR, BSR, NICE, PIDS/IDSA, Government of British Columbia, FDA) for condition-specific details.

Guideline relianceFollow specialty guideline recommendations for interval timing rather than a fixed numeric schedule.

CRP preferenceWhen either test is allowed, CRP is generally preferred due to reproducibility and clinical utility.

Monitoring intervals per disease guidance

Active arthritis monitoringMonitor disease activity every 1–3 months during active arthritis (e.g., RA) using composite measures that may include CRP or ESR; less frequent monitoring once target achieved.

Large vessel vasculitis (GCA)Visits including ESR/CRP measurements could be scheduled every 1–3 months during first year and every 3–6 months thereafter per EULAR.

SLE monitoringCRP testing at diagnosis and every 1–3 months during active disease, then 6–12 months once stabilized (BSR guidance).

ESR, CRP — ranges & definitions

CRP definitionC-reactive protein (CRP) — an acute phase protein synthesized by the liver that can rise >1000-fold during acute inflammation and is useful for monitoring inflammatory response.

ESR definition (Westergren)Erythrocyte sedimentation rate (ESR) — measures the distance red cells fall in a tube over one hour (Westergren method); results influenced by method and sample preparation.

LimitationsCRP and ESR are nonspecific; CRP may not reflect disease activity in SLE and ESR is influenced by fibrinogen, immunoglobulins, anemia, and other noninflammatory factors.

CRP frequency in SLE

SLE active disease monitoringCRP — test at diagnosis and every 1–3 months during active SLE; once stabilized, test every 6–12 months.

CRP role in SLECRP often low or normal in SLE unless infection; elevated ESR more common but less reliable for disease activity.

PregnancyBSR recommends CRP testing in mothers with SLE during pregnancy (frequency not specified).

CRP measurement in early AHO

Pediatric AHO early monitoringCRP — measure every 2–3 days during the early therapeutic course, then weekly or periodically until normalization or clear trend toward normalization.

CRP as serial baselineObtain serum CRP at initial evaluation to serve as baseline for sequential monitoring in pediatric AHO.

ESR roleESR is no longer used routinely to diagnose pediatric AHO per guideline; combined use with CRP may marginally improve sensitivity but thresholds are uncertain.

FREQUENCY LIMITS — additional notes

Additional frequency notes placeholderPolicy references multiple guideline sources for condition-specific monitoring intervals; consult cited guidelines for further details and supplemental frequency ranges.

No single scheduleBecause ranges vary by condition and guideline, no single universal frequency is specified in the policy.

Provider responsibilityOrdering clinicians should follow specialty guidance and document indication and timing on requisitions as required by jurisdiction or payer rules.

CRP sensitivity and specificity varied by timing relative to blood culture: low sensitivity near culture time, higher sensitivity 24–72 hours later but with lower specificity.

Clinical utility conclusionRoutine serial CRP testing did not improve outcomes and is of limited utility without other clinical indications.

Castleman disease lab threshold

Castleman disease minor criteriaNCCN: elevated CRP (>10 mg/L) or ESR (>15 mm/h) are listed as minor diagnostic criteria for idiopathic multicentric Castleman disease; CRP evaluation is mandatory and tracking CRP is highly recommended.

ESR acceptanceNCCN states ESR will be accepted if CRP is not available for Castleman disease assessment.

CRP preferenceCRP is emphasized as mandatory in the NCCN guidance for diagnostic evaluation of idiopathic MCD.

CRP thresholds for MIS-C and AHO monitoring

ACR MIS-C/Multisystem triggerACR: CRP ≥ 5 mg/L (or ESR ≥ 40 mm/h) in tier‑one lab testing is used as a trigger for further tier‑two evaluation in suspected multisystem inflammatory syndrome in children.

Pediatric AHO monitoringPediatric AHO guidance: measure CRP every 2–3 days early in therapy, then weekly or periodically until normalization to monitor response.

CRP as baseline and serial markerCRP is recommended as baseline lab at initial evaluation and for sequential monitoring in pediatric inflammatory syndromes and AHO.

Billing Rule

Use listed CPT codes; outpatient schedules may only reimburse CRP

CRP (86140, 86141) and ESR (85651, 85652) are listed as applicable procedure codes; note that some outpatient payment schedules (e.g., British Columbia) will perform ESR only if a written indication is provided and may only reimburse CRP when both tests are ordered together.

Applicable CPT codes: 85651, 85652, 86140, 86141
British Columbia outpatient schedule: ESR performed only with written indication; if CRP and ESR ordered together most outpatient labs will only perform CRP because only CRP is payable

Prior Authorization

No specified prior authorization for inflammatory marker testing

No explicit prior authorization requirements for ESR/CRP testing are specified in the provided policy text.

Authorization statements are contingent on benefit coverage per policy guidance, but no discrete PA process is defined here.

Step Therapy

CRP preferred; only CRP approved if both ordered where either allowed

When a condition allows either CRP or ESR, CRP is the preferred test and if both CRP and ESR are ordered where either is permitted, only CRP will be approved.

CRP is the preferred biomarker when either test is allowed.
Simultaneous ordering of CRP and ESR for a condition that allows either will result in approval of only CRP.

Step Therapy

Select CRP as first‑line test for undifferentiated inflammation

Clinical guidance and WHO/ASCP recommendations favor selecting CRP rather than ESR as the first-line acute‑phase test for undifferentiated inflammation due to CRP's superior early sensitivity and faster normalization.

CRP generally detects acute inflammation earlier than ESR and returns to normal more quickly.
WHO and specialty guidance recommend CRP as the preferred initial test in many settings.

Step Therapy

No step therapy required; guideline alternatives noted (e.g., fecal calprotectin for IBD)

No formal step therapy sequence is described in the policy; specialty societies note alternatives (for example, fecal calprotectin for IBD screening) and recommend using CRP when fecal markers are unavailable.

Policy does not impose step therapy prior to CRP/ESR.
AGA suggests fecal markers (e.g., calprotectin) rather than CRP/ESR for IBD screening; CRP may be used if fecal tests unavailable or not covered.

Documentation Required

Submit accurate documentation and use appropriate industry-standard coding

Providers must submit accurate documentation of services performed and use appropriate coding per industry standard coding guidelines; failure to follow coding/billing guidance may result in claim denial or recoupment.

Follow Uniform Billing, CPT, HCPCS, ICD‑10 and other industry coding guidance when submitting claims.
Accurate supporting documentation must be maintained and submitted as required.

Documentation Required

Document ESR within six months of Hodgkin lymphoma diagnosis and record elevated values

For Hodgkin lymphoma staging and follow‑up, document ESR measured within six months of diagnosis and record the ESR value when it was elevated at diagnosis for recommended follow-up laboratory studies.

NCCN: ESR should be tested within six months of diagnosis for Classic Hodgkin Lymphoma.
If ESR was elevated at diagnosis, include ESR in follow‑up labs per NCCN schedule.

Documentation Required

Document symptoms/signs and obtain baseline ESR/CRP when starting treatment for suspected GCA

When initiating treatment for suspected giant cell arteritis (GCA), document diagnostically relevant symptoms and signs and obtain baseline laboratory tests including full blood count, CRP and ESR either before or immediately after starting high‑dose glucocorticoids.

Document relevant clinical signs/symptoms at treatment initiation.
Obtain baseline FBC, CRP and ESR before or immediately after commencing high‑dose steroids.

Documentation Required

Provide written indication on requisition for outpatient ESR where required

Some jurisdictions require that a written clinical indication be provided on the laboratory requisition when ordering outpatient ESR; providers should include the indication when applicable.

British Columbia outpatient payment schedule: ESR performed only if a written indication is provided on the requisition.
Include a clear clinical indication when ordering ESR in jurisdictions that require it.

Documentation Required

Reference policy publication and effective dates for documentation expectations

Refer to the policy publication history: governance approved the document on 06/16/2026 and the policy effective date is 2026‑10‑01 for documentation and compliance reference.

Governance approval: 06/16/2026.
Effective date: 10/01/2026.

Denial Risk

Claims risk: denials or recoupment for non‑compliant coding or unsupported ESR testing

Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed; ordering ESR for individuals without a diagnosed inflammatory condition does not meet criteria and may be subject to denial or recoupment.

Failure to follow coding/billing guidelines can lead to denials/recoupment.
ESR ordered for individuals without a diagnosed inflammatory condition does not meet criteria and may be denied.

Denial Risk

Avoid ordering CRP and ESR simultaneously; only CRP approved if both ordered

Ordering both CRP and ESR simultaneously is discouraged because measuring multiple inflammatory markers together does not substantially improve diagnostic accuracy; when both are ordered where either is allowed, only CRP will be approved.

Testing multiple inflammatory markers simultaneously generally does not increase diagnostic ability and should be avoided.
If both CRP and ESR are ordered for a condition that allows either, only CRP will be approved.

Billing Rule

Outpatient ESR may require documented indication; labs may only perform/pay CRP when both ordered

Some outpatient payment schedules (example: British Columbia) require written indication on the requisition for ESR and may only perform ESR if explicitly justified; labs may only perform CRP when both tests are ordered because only CRP is payable.

British Columbia guidance: ESR will be performed only with written indication; if both ordered most outpatient labs will only perform CRP because only CRP is payable.
Ensure documentation of indication when ordering ESR in such jurisdictions to avoid non‑performance or non‑payment.

Denial Risk

No additional explicit denial triggers specified in these sections

No explicit payer denial triggers beyond the coding/billing and reimbursement guidance are specified in the provided document sections.

Policy sections reviewed do not list discrete administrative denial rules other than standard coding/billing compliance and coverage criteria.

PMR: baseline labs including CRP and/or ESR prior to therapy; monitoring per BSR/ACR guidance.
Early arthritis: monitor disease activity with CRP/ESR at intervals usually every 1–3 months until treatment target reached.

Note

No explicit restriction on who may order ESR/CRP

The policy does not restrict which clinicians may order ESR or CRP; recommendations apply to primary and specialty care contexts and testing is typically ordered at clinic visits as clinically indicated.

No explicit ordering‑provider restrictions are listed in these sections.
Primary care and specialists may order testing following clinical guidance.

Billing Rule

Request hsCRP explicitly; include indication for ESR where required

If high‑sensitivity CRP (hsCRP) is desired for cardiovascular risk stratification, it must be specifically requested on the laboratory requisition; ESR may require an indication on requisition in some jurisdictions.

Request hsCRP explicitly on the requisition for cardiovascular risk use.
Include clinical indication for ESR on outpatient requisitions where required (e.g., British Columbia).

Note

No explicit ordering‑provider restrictions in these sections

These policy sections do not impose ordering‑provider restrictions; follow local and payer rules where applicable.

No additional ordering‑provider limitations are specified in the reviewed sections.

ICSH found many labs use non‑Westergren methods with potential deviations up to 142%; labs using alternate methods should consider adding interpretive comments.

Factors affecting ESRESR is influenced by sample preparation, red cell morphology, anemia, renal disease, obesity, and ambient conditions.

CRP — clinical limitations

CRP clinical caveatCRP rises in many inflammatory conditions, tissue damage, and bacterial infections but may not reflect disease activity in SLE due to interferon effects or complex formation.

Interpretation in infection vs autoimmunityA markedly raised CRP is more suggestive of infection than of autoimmune activity in some contexts (e.g., SLE).

Use in monitoringCRP is useful for serial monitoring due to rapid rise and fall compared with ESR, but interpret in clinical context and with other data.

ESR — clinical limitations

ESR — nonspecific markerESR is a nonspecific inflammation marker influenced by fibrinogen and immunoglobulins and may be elevated in conditions like SLE due to hypergammaglobulinemia rather than active inflammation.

Guideline useESR is used in some guidelines (e.g., NCCN for Hodgkin lymphoma staging) where its value influences treatment decisions.

Limitations for disease activityESR may not reliably distinguish infection from autoimmune activity and is affected by many noninflammatory factors.

Inflammation markers (CRP, ESR)

Inflammation markers overviewCRP and ESR are laboratory measures used to assess and monitor systemic inflammation; CRP is generally preferred where allowed due to reproducibility.

Complementary rolesBoth markers can be used complementarily in specific conditions, but simultaneous routine ordering is discouraged if one marker suffices.

Clinical context requiredInterpretation requires correlation with clinical findings, imaging, and microbiologic testing when applicable.

Laboratory‑developed tests (LDTs)

Laboratory‑developed tests (LDTs)LDTs for CRP and ESR are performed in‑house and regulated under CLIA as high‑complexity tests; they are not FDA‑approved but may be used clinically after validation.

Regulatory oversightCMS/CLIA oversee LDTs; FDA has approved multiple CRP and ESR systems but LDTs remain common.

Laboratory standardsTesting should be performed in laboratories meeting CLIA quality standards and relevant certification requirements.

hsCRP

hsCRP assayHigh‑sensitivity CRP (hsCRP) is a distinct CRP assay variant used for cardiovascular risk stratification and should be specifically requested when desired.

Separate codinghsCRP is separately coded (86141) and differs from conventional CRP (86140) in intended use and analytic sensitivity.

Ordering noteSpecify hsCRP on requisition when cardiovascular risk assessment is the clinical aim.

Guidance sources for CRP and ESR

Guidance sourcesPolicy cites multiple specialty guideline sources (EULAR, ACR, BSR/BHPR, NICE, PIDS/IDSA) and regulatory reviews (FDA) for CRP/ESR use and monitoring recommendations.

Condition‑specific guidanceRefer to the cited guidelines for disease‑specific frequency ranges and monitoring strategies (examples provided in policy Notes).

Evidence referencesSee policy references section for original guideline and evidence citations supporting recommendations.